âš¡Glenmark Announces 400 mg 'FabiFlu' for COVID-19 Treatment
By IANS
Glenmark Pharmaceuticals, a research-led global pharmaceutical company, on Thursday announced that it is set to introduce a 400 mg version of oral antiviral - FabiFlu -- for the treatment of mild to moderate Covid-19 in India.